<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209218</url>
  </required_header>
  <id_info>
    <org_study_id>2019-234</org_study_id>
    <nct_id>NCT04209218</nct_id>
  </id_info>
  <brief_title>Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery</brief_title>
  <official_title>Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative
      complications remains high and patients' long-term outcome is still challenging. In addition
      to surgery, anesthetic management particularly intraoperative blood pressure management and
      use of dexamethasone may affect patients' early and long-term outcomes after surgery for
      NSCLC. This study aims to investigate the impact of intraoperative blood pressure management
      and dexamethasone administration on early and long-term outcomes in patients undergoing
      surgery for lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical resection is the main treatment for patients with non-small cell lung cancer (NSCLC)
      and continuous efforts have been made to evolve surgical strategies and techniques. It has
      been now been realized that perioperative period is characterized with profound changes and
      anesthesia management may also affect outcomes of patients after cancer surgery.

      Even under well controlled conditions, blood pressure fluctuation frequently occurs during
      anesthesia and surgery. In previous studies, intraoperative hypotension was associated with
      increased risk of organ injuries (such as delirium, acute kidney injury, myocardial injury,
      and stroke) and higher 1-year mortality. Unpublished data showed that intraoperative
      hypotension was also associated with shortened long-term survival in patients after lung
      cancer surgery. In a recent trial, individualized intraoperative blood pressure management
      which avoided intraoperative hypotension decreased the incidence of postoperative organ
      injury when compared with routine practice. Avoiding intraoperative hypotension may also
      prolong survival after lung cancer surgery. However, evidences are lacking regarding this
      topic.

      Dexamethasone is frequently used for prevention of postoperative nausea and vomiting. Studies
      showed that a single low-dose dexamethasone has anti-inflammatory effect and can regulate
      immune function. It has been shown that perioperative dexamethasone can improve analgesia
      after surgery. In retrospective studies, perioperative low-dose dexamethasone was associated
      with less wound infection and improved long-term survival in patients after surgeries for
      pancreatic and lung cancer. It is hypothesized that intraoperative dexamethasone may reduce
      postoperative complications and improve long-term survival after lung cancer surgery.
      Interventional studies are required to confirm this hypothesis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>A 2 × 2 factorial randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>For dexamethasone administration, all participants, care providers, investigators, and outcomes assessors are masked. For blood pressure management, participants and outcome assessors are masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival within 3 years after surgery</measure>
    <time_frame>Up to 3 years after surgery</time_frame>
    <description>Overall survival within 3 years after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of postoperative complications within 30 days (substudy)</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Postoperative complications are generally defined as newly occurred medical conditions that are harmful to patients' recovery and required interventional therapy; including but not limited to delirium, acute kidney injury, myocardial injury, and other complications after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival within 3 years after surgery</measure>
    <time_frame>Up to 3 years after surgery</time_frame>
    <description>Recurrence-free survival within 3 years after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-specific survival within 3 years after surgery</measure>
    <time_frame>Up to 3 years after surgery</time_frame>
    <description>Cancer-specific survival within 3 years after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of 1-year survivors</measure>
    <time_frame>At the end of the 1st year after surgery</time_frame>
    <description>Quality of life is assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-30, score ranges from 0 to 100, with higher score indicating better function) and Quality of Life Questionnaire Lung Cancer-13 (QLQ LC-13, score ranges from 0 to 100, with higher score indicating better function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of organ injury and other complications within 5 days after surgery (substudy)</measure>
    <time_frame>Up to 5 days after surgery</time_frame>
    <description>A composite endpoint including delirium, acute kidney injury, myocardial injury, and other complications after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of admission to the intensive care unit after surgery (substudy)</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Admission to the intensive care unit after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the intensive care unit after surgery (substudy)</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Length of stay in the intensive care unit after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital after surgery (substudy)</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Length of stay in hospital after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of 30-day all-cause mortality (substudy)</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Death due to any cause within 30 days after surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain score within 3 days after surgery (substudy)</measure>
    <time_frame>Up to 3 days after surgery</time_frame>
    <description>Pain score is assessed with the Numeric Rating Scale, an 11-point scale where 0=no pain and 10=the worst pain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective sleep quality score within 3 days after surgery (substudy)</measure>
    <time_frame>Up to 3 days after surgery</time_frame>
    <description>Subjective sleep quality is assessed with the Numeric Rating Scale, an 11-point scale where 0=the best sleep and 10=the worst sleep.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1988</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Surgery</condition>
  <condition>Blood Pressure Management</condition>
  <condition>Dexamethasone</condition>
  <condition>Overall Survival</condition>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Routine blood pressure management + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blood pressure is maintained according to routine practice. Placebo (normal saline 2 ml) is administered before anesthesia induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine blood pressure management + dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood pressure is maintained according to routine practice. Dexamethasone (10 mg/2 ml) ia administered before anesthesia induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Targeted blood pressure management + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood pressure is maintained within ±10% from baseline. Placebo (normal saline 2 ml) is administered before anesthesia induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Targeted blood pressure management + dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood pressure is maintained within ±10% from baseline. Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.</description>
    <arm_group_label>Routine blood pressure management + dexamethasone</arm_group_label>
    <arm_group_label>Targeted blood pressure management + dexamethasone</arm_group_label>
    <other_name>Glucocorticoids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Targeted blood pressure management</intervention_name>
    <description>Blood pressure is maintained within ±10% from baseline.</description>
    <arm_group_label>Targeted blood pressure management + dexamethasone</arm_group_label>
    <arm_group_label>Targeted blood pressure management + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (2 ml normal saline) is administered before anesthesia induction.</description>
    <arm_group_label>Routine blood pressure management + placebo</arm_group_label>
    <arm_group_label>Targeted blood pressure management + placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine blood presure management</intervention_name>
    <description>Blood pressure is maintained according to routine practice.</description>
    <arm_group_label>Routine blood pressure management + dexamethasone</arm_group_label>
    <arm_group_label>Routine blood pressure management + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged &gt;50 years but &lt;90 years.

          -  Diagnosed as resectable primary non-small cell lung cancer (stage IA-IIIA) and
             scheduled for radical surgery with an expected duration of &gt;2 hours.

          -  Agree to participate in this study and sign the informed consent.

        Exclusion Criteria:

          -  Clinical examinations suggest non-resectable lung cancer or patients scheduled for a
             biopsy surgery.

          -  Recurrent or metastatic lung cancer.

          -  History of cancer or complicated with cancer in other organs.

          -  Long-term exposure to glucocorticoids or other immunosuppressant(s) due to autoimmune
             disease or organ transplantation.

          -  Uncontrolled hypertension (systolic blood pressure &gt;180 mmHg or diastolic blood
             pressure &gt;110 mmHg); or requirement of vasopressors to maintain blood pressure.

          -  Persistent atrial fibrillation, or acute cardiovascular events (acute coronary
             syndrome, stroke, or congestive heart failure) within 3 months.

          -  Severe hepatic dysfunction (Child-Pugh C) or renal failure (requirement of renal
             replacement therapy).

          -  Any other circumstances considered unsuitable for study participation by attending
             physicians or investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Xin Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Xin Wang, MD, PhD</last_name>
    <phone>86 (10) 83572784</phone>
    <email>wangdongxin@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen-Wen Huang, MD</last_name>
    <phone>86 (10) 83572460</phone>
    <email>hww9215@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Xin Wang, MD, PhD</last_name>
      <phone>86 (10) 83572784</phone>
      <email>wangdongxin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi-Bin Hua, MD</last_name>
      <phone>86 (10) 83572460</phone>
      <email>huayibin@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wen-Wen Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong-Xin Wang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Sullivan R, Alatise OI, Anderson BO, Audisio R, Autier P, Aggarwal A, Balch C, Brennan MF, Dare A, D'Cruz A, Eggermont AM, Fleming K, Gueye SM, Hagander L, Herrera CA, Holmer H, Ilbawi AM, Jarnheimer A, Ji JF, Kingham TP, Liberman J, Leather AJ, Meara JG, Mukhopadhyay S, Murthy SS, Omar S, Parham GP, Pramesh CS, Riviello R, Rodin D, Santini L, Shrikhande SV, Shrime M, Thomas R, Tsunoda AT, van de Velde C, Veronesi U, Vijaykumar DK, Watters D, Wang S, Wu YL, Zeiton M, Purushotham A. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015 Sep;16(11):1193-224. doi: 10.1016/S1470-2045(15)00223-5. Review.</citation>
    <PMID>26427363</PMID>
  </reference>
  <reference>
    <citation>Vansteenkiste J, Crinò L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P, Veronesi G, Stahel R, Peters S, Felip E; Panel Members. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014 Aug;25(8):1462-74. doi: 10.1093/annonc/mdu089. Epub 2014 Feb 20.</citation>
    <PMID>24562446</PMID>
  </reference>
  <reference>
    <citation>Emmert A, Straube C, Buentzel J, Roever C. Robotic versus thoracoscopic lung resection: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Sep;96(35):e7633. doi: 10.1097/MD.0000000000007633. Review.</citation>
    <PMID>28858083</PMID>
  </reference>
  <reference>
    <citation>Ciechanowicz SJ, Ma D. Anaesthesia for oncological surgery - can it really influence cancer recurrence? Anaesthesia. 2016 Feb;71(2):127-31. doi: 10.1111/anae.13342. Epub 2015 Dec 16.</citation>
    <PMID>26669960</PMID>
  </reference>
  <reference>
    <citation>Kim R. Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer Metastasis Rev. 2017 Mar;36(1):159-177. doi: 10.1007/s10555-016-9647-8. Review.</citation>
    <PMID>27866303</PMID>
  </reference>
  <reference>
    <citation>Byrne K, Levins KJ, Buggy DJ. Can anesthetic-analgesic technique during primary cancer surgery affect recurrence or metastasis? Can J Anaesth. 2016 Feb;63(2):184-92. Review.</citation>
    <PMID>26497721</PMID>
  </reference>
  <reference>
    <citation>Mascha EJ, Yang D, Weiss S, Sessler DI. Intraoperative Mean Arterial Pressure Variability and 30-day Mortality in Patients Having Noncardiac Surgery. Anesthesiology. 2015 Jul;123(1):79-91. doi: 10.1097/ALN.0000000000000686.</citation>
    <PMID>25929547</PMID>
  </reference>
  <reference>
    <citation>Lonjaret L, Lairez O, Minville V, Geeraerts T. Optimal perioperative management of arterial blood pressure. Integr Blood Press Control. 2014 Sep 12;7:49-59. doi: 10.2147/IBPC.S45292. eCollection 2014. Review.</citation>
    <PMID>25278775</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, MacKenzie CR, Gold JP, Ales KL, Topkins M, Shires GT. Preoperative characteristics predicting intraoperative hypotension and hypertension among hypertensives and diabetics undergoing noncardiac surgery. Ann Surg. 1990 Jul;212(1):66-81.</citation>
    <PMID>2363606</PMID>
  </reference>
  <reference>
    <citation>Bijker JB, van Klei WA, Vergouwe Y, Eleveld DJ, van Wolfswinkel L, Moons KG, Kalkman CJ. Intraoperative hypotension and 1-year mortality after noncardiac surgery. Anesthesiology. 2009 Dec;111(6):1217-26. doi: 10.1097/ALN.0b013e3181c14930.</citation>
    <PMID>19934864</PMID>
  </reference>
  <reference>
    <citation>Monk TG, Bronsert MR, Henderson WG, Mangione MP, Sum-Ping ST, Bentt DR, Nguyen JD, Richman JS, Meguid RA, Hammermeister KE. Association between Intraoperative Hypotension and Hypertension and 30-day Postoperative Mortality in Noncardiac Surgery. Anesthesiology. 2015 Aug;123(2):307-19. doi: 10.1097/ALN.0000000000000756. Erratum in: Anesthesiology. 2016 Mar;124(3):741-2.</citation>
    <PMID>26083768</PMID>
  </reference>
  <reference>
    <citation>Scholz AF, Oldroyd C, McCarthy K, Quinn TJ, Hewitt J. Systematic review and meta-analysis of risk factors for postoperative delirium among older patients undergoing gastrointestinal surgery. Br J Surg. 2016 Jan;103(2):e21-8. doi: 10.1002/bjs.10062. Epub 2015 Dec 16. Review.</citation>
    <PMID>26676760</PMID>
  </reference>
  <reference>
    <citation>Futier E, Lefrant JY, Guinot PG, Godet T, Lorne E, Cuvillon P, Bertran S, Leone M, Pastene B, Piriou V, Molliex S, Albanese J, Julia JM, Tavernier B, Imhoff E, Bazin JE, Constantin JM, Pereira B, Jaber S; INPRESS Study Group. Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery: A Randomized Clinical Trial. JAMA. 2017 Oct 10;318(14):1346-1357. doi: 10.1001/jama.2017.14172.</citation>
    <PMID>28973220</PMID>
  </reference>
  <reference>
    <citation>Younes RN, Rogatko A, Brennan MF. The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases. Ann Surg. 1991 Aug;214(2):107-13.</citation>
    <PMID>1867517</PMID>
  </reference>
  <reference>
    <citation>Park SY, Lee JG, Kim J, Bae MK, Lee CY, Kim DJ, Chung KY. The influence of smoking intensity on the clinicopathologic features and survival of patients with surgically treated non-small cell lung cancer. Lung Cancer. 2013 Sep;81(3):480-486. doi: 10.1016/j.lungcan.2013.07.002. Epub 2013 Jul 26.</citation>
    <PMID>23896023</PMID>
  </reference>
  <reference>
    <citation>Yu HC, Luo YX, Peng H, Wang XL, Yang ZH, Huang MJ, Kang L, Wang L, Wang JP. Association of perioperative blood pressure with long-term survival in rectal cancer patients. Chin J Cancer. 2016 Apr 11;35:38. doi: 10.1186/s40880-016-0100-8.</citation>
    <PMID>27067550</PMID>
  </reference>
  <reference>
    <citation>Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, Watcha M, Chung F, Angus S, Apfel CC, Bergese SD, Candiotti KA, Chan MT, Davis PJ, Hooper VD, Lagoo-Deenadayalan S, Myles P, Nezat G, Philip BK, Tramèr MR; Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014 Jan;118(1):85-113. doi: 10.1213/ANE.0000000000000002. Erratum in: Anesth Analg. 2014 Mar;118(3):689. Anesth Analg. 2015 Feb;120(2):494.</citation>
    <PMID>24356162</PMID>
  </reference>
  <reference>
    <citation>Bain CR, Draxler DF, Taylor R, Wallace S, Gouldthorpe O, Corcoran TB, Myles PS, L Medcalf R, Bozaoglu K. The early in-vivo effects of a single anti-emetic dose of dexamethasone on innate immune cell gene expression and activation in healthy volunteers. Anaesthesia. 2018 Aug;73(8):955-966. doi: 10.1111/anae.14306. Epub 2018 May 28.</citation>
    <PMID>29806695</PMID>
  </reference>
  <reference>
    <citation>Polderman JAW, Farhang-Razi V, van Dieren S, Kranke P, DeVries JH, Hollmann MW, Preckel B, Hermanides J. Adverse side-effects of dexamethasone in surgical patients - an abridged Cochrane systematic review. Anaesthesia. 2019 Jul;74(7):929-939. doi: 10.1111/anae.14610. Epub 2019 Mar 1.</citation>
    <PMID>30821852</PMID>
  </reference>
  <reference>
    <citation>Toner AJ, Ganeshanathan V, Chan MT, Ho KM, Corcoran TB. Safety of Perioperative Glucocorticoids in Elective Noncardiac Surgery: A Systematic Review and Meta-analysis. Anesthesiology. 2017 Feb;126(2):234-248. doi: 10.1097/ALN.0000000000001466. Review.</citation>
    <PMID>27922839</PMID>
  </reference>
  <reference>
    <citation>Asehnoune K, Futier E, Feuillet F, Roquilly A; PACMAN group. PACMAN trial protocol, Perioperative Administration of Corticotherapy on Morbidity and mortality After Non-cardiac major surgery: a randomised, multicentre, double-blind, superiority study. BMJ Open. 2019 Mar 23;9(3):e021262. doi: 10.1136/bmjopen-2017-021262.</citation>
    <PMID>30904834</PMID>
  </reference>
  <reference>
    <citation>Call TR, Pace NL, Thorup DB, Maxfield D, Chortkoff B, Christensen J, Mulvihill SJ. Factors associated with improved survival after resection of pancreatic adenocarcinoma: a multivariable model. Anesthesiology. 2015 Feb;122(2):317-24. doi: 10.1097/ALN.0000000000000489.</citation>
    <PMID>25305092</PMID>
  </reference>
  <reference>
    <citation>Huang WW, Zhu WZ, Mu DL, Ji XQ, Nie XL, Li XY, Wang DX, Ma D. Perioperative Management May Improve Long-term Survival in Patients After Lung Cancer Surgery: A Retrospective Cohort Study. Anesth Analg. 2018 May;126(5):1666-1674. doi: 10.1213/ANE.0000000000002886.</citation>
    <PMID>29517574</PMID>
  </reference>
  <reference>
    <citation>Xu H, Shu SH, Wang D, Chai XQ, Xie YH, Zhou WD. Goal-directed fluid restriction using stroke volume variation and cardiac index during one-lung ventilation: a randomized controlled trial. J Thorac Dis. 2017 Sep;9(9):2992-3004. doi: 10.21037/jtd.2017.08.98.</citation>
    <PMID>29221272</PMID>
  </reference>
  <reference>
    <citation>Dinic VD, Stojanovic MD, Markovic D, Cvetanovic V, Vukovic AZ, Jankovic RJ. Enhanced Recovery in Thoracic Surgery: A Review. Front Med (Lausanne). 2018 Feb 5;5:14. doi: 10.3389/fmed.2018.00014. eCollection 2018. Review.</citation>
    <PMID>29459895</PMID>
  </reference>
  <reference>
    <citation>Khwannimit B, Bhurayanontachai R. Prediction of fluid responsiveness in septic shock patients: comparing stroke volume variation by FloTrac/Vigileo and automated pulse pressure variation. Eur J Anaesthesiol. 2012 Feb;29(2):64-9. doi: 10.1097/EJA.0b013e32834b7d82.</citation>
    <PMID>21946822</PMID>
  </reference>
  <reference>
    <citation>Piccioni F, Bernasconi F, Tramontano GTA, Langer M. A systematic review of pulse pressure variation and stroke volume variation to predict fluid responsiveness during cardiac and thoracic surgery. J Clin Monit Comput. 2017 Aug;31(4):677-684. doi: 10.1007/s10877-016-9898-5. Epub 2016 Jun 15. Review.</citation>
    <PMID>27306799</PMID>
  </reference>
  <reference>
    <citation>Suehiro K, Okutani R. Stroke volume variation as a predictor of fluid responsiveness in patients undergoing one-lung ventilation. J Cardiothorac Vasc Anesth. 2010 Oct;24(5):772-5. doi: 10.1053/j.jvca.2010.03.014. Epub 2010 Jul 17.</citation>
    <PMID>20638869</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Chen CQ, Lei XZ, Feng ZY, Zhu SM. Goal-directed fluid optimization based on stroke volume variation and cardiac index during one-lung ventilation in patients undergoing thoracoscopy lobectomy operations: a pilot study. Clinics (Sao Paulo). 2013 Jul;68(7):1065-70. doi: 10.6061/clinics/2013(07)27.</citation>
    <PMID>23917675</PMID>
  </reference>
  <reference>
    <citation>Loop T. Fast track in thoracic surgery and anaesthesia: update of concepts. Curr Opin Anaesthesiol. 2016 Feb;29(1):20-5. doi: 10.1097/ACO.0000000000000282. Review.</citation>
    <PMID>26658180</PMID>
  </reference>
  <reference>
    <citation>Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, Speroff T, Gautam S, Bernard GR, Inouye SK. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001 Jul;29(7):1370-9.</citation>
    <PMID>11445689</PMID>
  </reference>
  <reference>
    <citation>Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k. doi: 10.1093/eurheartj/ehu283. Epub 2014 Aug 29. Erratum in: Eur Heart J. 2015 Oct 14;36(39):2666. Eur Heart J. 2015 Oct 14;36(39):2642.</citation>
    <PMID>25173341</PMID>
  </reference>
  <reference>
    <citation>Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017 Jan;151(1):193-203. doi: 10.1016/j.chest.2016.10.010. Epub 2016 Oct 22. Review.</citation>
    <PMID>27780786</PMID>
  </reference>
  <reference>
    <citation>Kellum JA, Lameire N; KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013 Feb 4;17(1):204. doi: 10.1186/cc11454. Review.</citation>
    <PMID>23394211</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Xin Wang</investigator_full_name>
    <investigator_title>Chairman, Department of Anaesthesiology and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Radical Resection</keyword>
  <keyword>Blood Pressure Management</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Overall Survival</keyword>
  <keyword>Postoperative Complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

